International Survey of Acute Coronavirus Syndromes-COVID-19
ConditionCOVID-19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Bologna
About this trial
In response to the COVID-19 crisis, ISACS-TC has promoted a new registry of the existing and further centers of the same geographic areas to support clinical research to prevent, and treat the COVID-19 illness. These efforts are made possible by the generous contributions of clinical research volunteers in some of the countries participating to the prior acute coronary syndrome network.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years (male or female)
Patients admitted to any hospital center with a confirmed diagnosis of COVID-19 infection.
Disqualifiers
None
Trial population
Confirmed diagnosis of COVID-19 infection.
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Observational (registry)
Combination productObservational (Patient Registry)
Treatment groups
10,000 Participants
are divided into 10 treatment groups10
Treatment groupsSee each treatment group below.
Group A: Male1 intervention
Group B: Female1 intervention
Group C: Elderly1 intervention
Group D: Hypertension1 intervention
Group E: Diabetes1 intervention
Group F: Dyslipidemias1 intervention
Group G: Smoking1 intervention
Group H: Kidney Disease1 intervention
Group I: Heart Diseases1 intervention
Group J: Vascular diseases1 intervention
Trial outcomes
Primary outcomes
1
Death all cause
Occurrence of all cause death
Time frame
30-day2
Death all cause
Occurrence of all cause death
Time frame
6 month3
Death all cause
Occurrence of all cause death
Time frame
12-monthSecondary outcomes
1
Heart failure
Occurrence of heart failure or worsening of preexisting heart failure (According to the attending physician)
Time frame
30 day, 6 -12 months2
Worsening renal function
Occurrence of kidney disease or worsening of preexisting kidney failure (According to the attending physician)
Time frame
30 day, 6 -12 months3
Respiratory Insufficiency
Occurrence of respiratory insufficiency or worsening of preexisting respiratory insufficiency (According to the attending physician)
Time frame
30 day, 6 -12 months4
Pneumonia
Occurrence of pneumonia (According to the attending physician)
Time frame
30 day, 6 -12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Bologna
Lead sponsor
Associazione Per La Ricerca Cardiologica (Roma)
Collaborator
Source ClinicalTrials.gov